GNTL.F Stock Overview
A molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genetic Technologies Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.07 |
| 52 Week Low | AU$0.01 |
| Beta | 0.50 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -95.00% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNTL.F | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -1.6% |
| 1Y | n/a | 17.9% | 30.8% |
Return vs Industry: Insufficient data to determine how GNTL.F performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how GNTL.F performed against the US Market.
Price Volatility
| GNTL.F volatility | |
|---|---|
| GNTL.F Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 7.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GNTL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GNTL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 55 | Simon Morriss | genetype.com |
Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people’s health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies Limited Fundamentals Summary
| GNTL.F fundamental statistics | |
|---|---|
| Market cap | US$3.72m |
| Earnings (TTM) | -US$7.88m |
| Revenue (TTM) | US$6.34m |
0.6x
P/S Ratio-0.5x
P/E RatioIs GNTL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNTL.F income statement (TTM) | |
|---|---|
| Revenue | AU$9.67m |
| Cost of Revenue | AU$3.76m |
| Gross Profit | AU$5.91m |
| Other Expenses | AU$17.93m |
| Earnings | -AU$12.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 61.12% |
| Net Profit Margin | -124.24% |
| Debt/Equity Ratio | 35.2% |
How did GNTL.F perform over the long term?
See historical performance and comparison